Current Indications for Chemotherapy in Prostate Cancer Patients
- 31 January 2007
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 51 (1), 17-26
- https://doi.org/10.1016/j.eururo.2006.08.013
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and SurvivalJournal of Clinical Oncology, 2001
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate CancerJNCI Journal of the National Cancer Institute, 1999
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.Journal of Clinical Oncology, 1998
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989